线粒体靶向治疗是对抗能量依赖性癌症的一种有吸引力的方法。然而，仍需要高效的线粒体器官治疗药物。在此，我们报告了一种线粒体靶向治疗平台，称为CDM@MUiO-DP@MCHM，由巨噬细胞-癌症混合膜(MCHM)封装的MUiO-66金属有机框架(MOFs)和载有微小RNA(miRNA)生物标志物检测探针(DP)的组成, 用于癌症诊断及以负责线粒体铜缺乏的部分(CDM)抑制癌症生长。使用裸鼠携带MCF-7的模型，经由裸鼠尾静脉注射，MCHM的封装不仅可以极大地增强纳米粒子(NPs)的癌症靶向能力，而且还赋予了NPs免疫逃逸的能力，从而延长循环时间。同时，利用荧光信号检测miRNA-21生物标志物以进行诊断，在线粒体膜电势缺乏和受损的情况下诱导能量缺乏，导致癌细胞的凋亡。CDM@MUiO-DP@MCHM良好的表现表明其具有巨大的线粒体器官治疗潜力。本文受版权保护。版权所有，转载请注明出处。

Mitochondria-targeted therapeutics is an attractive approach against energy-dependent cancer. However, the effective mitochondria organelle therapeutics agents still highly desirable. Herein, we report a mitochondria-targeted therapeutics platform, termed CDM@MUiO-DP@MCHM, consisted of macrophages-cancer hybrid membrane (MCHM) encapsulated MUiO-66 metal-organic frameworks (MOFs), which was loaded with microRNA (miRNA) biomarker detection probe (DP) for cancer diagnosis and copper-depleting moiety (CDM) for mitochondrial copper depletion to suppress cancer growth. Using nude mice bearing MCF-7 as model, after injected intravenously via the caudal vein of mice, the encapsulation of MCHM can not only greatly enhance the cancer homing-targeting ability of the nanoparticles (NPs), but also endows the NPs the immune escape capacity to extend the circulation time. The miRNA-21 biomarker could be detected by the fluorescence signal for diagnosis, while the CDM induced energy deficiency of and compromised mitochondria membrane potential, leading to apoptosis of the cancer cell. The good performance of CDM@MUiO-DP@MCHM suggest the great potential mitochondria organelle therapeutics. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.